Platelet P2Y12 receptor inhibition by thienopyridines: status and future.

abstract：:Myocardial protection through pharmacological approaches represents a large therapeutic challenge and is an important therapeutic strategy in patients with coronary artery disease, particularly after myocardial infarction. Extensive animal experiments have repeatedly demonstrated the efficacy of sodium-hydrogen exchan...

journal_title：Expert opinion on investigational drugs

authors： Karmazyn M

更新日期：2000-05-01 00:00:00

abstract：BACKGROUND:The hypereosinophilic syndrome (HES) comprises a heterogeneous group of disorders characterized by chronic, unexplained hypereosinophilia with organ involvement. The discovery of novel molecular targets has changed the therapeutic paradigm in HES. OBJECTIVE:This article reviews the current medical managemen...

journal_title：Expert opinion on investigational drugs

authors： Quintás-Cardama A,Cortes J

更新日期：2008-07-01 00:00:00

abstract：:Preclinical studies suggest that the brain corticotropin-releasing factor (CRF) systems mediate anxiety-like behavioural and somatic responses through actions at the CRF1 receptor. CRF1 antagonists block the anxiogenic-like effects of CRF and stress in animal models. Cerebrospinal fluid levels of CRF are elevated in s...

journal_title：Expert opinion on investigational drugs

authors： Zorrilla EP,Koob GF

更新日期：2004-07-01 00:00:00

abstract：:Diminished efficacy in terms of clinical relapses and lesion load on magnetic resonance images for patients developing neutralising antibodies (NAbs) to recombinant IFN-beta may be found in multiple sclerosis. NAbs become detectable over the first few years of therapy, disappearing during the treatment course in some ...

journal_title：Expert opinion on investigational drugs

authors： Bagnato F,Pozzilli C

更新日期：2003-07-01 00:00:00

abstract：INTRODUCTION:The ubiquitin-proteasome system (UPS) is responsible for the degradation of misfolded or damaged proteins, regulating inflammatory processes and cell cycle progression. The aim of this article is to summarize the currently available data regarding the possible utility of proteasome inhibitors (PIs) in the ...

journal_title：Expert opinion on investigational drugs

authors： Kandilis AN,Karidis NP,Kouraklis G,Patsouris E,Vasileiou I,Theocharis S

更新日期：2014-01-01 00:00:00

abstract：:The interaction between the urokinase receptor (uPAR) and its ligand urokinase (uPA) mediates phenomena such as tissue remodelling, chemotaxis, tumour invasion, dissemination, proliferation, and angiogenesis. The broad-spectrum of biological processes that the uPA/uPAR interaction plays a role in has led researchers t...

journal_title：Expert opinion on investigational drugs

authors： Weidle UH,König B

更新日期：1998-03-01 00:00:00

abstract：:Clinical trials of several platelet glycoprotein (GP) IIb/IIIa receptor inhibitors have demonstrated an unequivocal benefit of this potent antithrombotic therapy in high-risk patients with acute coronary syndromes (ACS) as well as in those undergoing percutaneous coronary intervention. In all of these major trials, ho...

journal_title：Expert opinion on investigational drugs

authors： Salam AM

更新日期：2003-09-01 00:00:00

abstract：:Psoriasis is a common skin disease which is characterised by the proliferation and abnormal differentiation of keratinocytes, coupled with complex immune disturbances. The beneficial effects of vitamin D derivatives in this disease are due to their capacity to inhibit proliferation, their ability to induce normal diff...

journal_title：Expert opinion on investigational drugs

authors： Guilhou JJ

更新日期：1998-01-01 00:00:00

abstract：:Parasitic infections are widespread in developing countries and frequently associated with immunocompromised patients in developed countries. Consequently, such infections are responsible for a significant amount of human mortality, morbidity and economic hardship. A growing consensus has identified the urgent need fo...

journal_title：Expert opinion on investigational drugs

authors： Soeiro MN,De Souza EM,Stephens CE,Boykin DW

更新日期：2005-08-01 00:00:00

abstract：INTRODUCTION:Psychostimulants are first-line treatments for attention-deficit/hyperactivity disorder (ADHD), but their tolerability profiles and individual response variability fuel a continuing search for alternative medications. The observation that nicotinic agents improve cognition has led pharmaceutical companies ...

journal_title：Expert opinion on investigational drugs

authors： Fleisher C,McGough J

更新日期：2014-08-01 00:00:00

abstract：:Recently there have been considerable advances made in the treatment of multiple sclerosis. For the first time since its initial clinical description in the 1800s, there are now available several medications which unequivocally exert favourable clinical effects through the lowering of the biological activity of the hu...

journal_title：Expert opinion on investigational drugs

authors： Goodin DS

更新日期：2000-04-01 00:00:00

abstract：INTRODUCTION:Epidermal growth factor receptor (EGFR) targeted treatment has been evaluated but has not shown a clear clinical benefit for breast cancer. This review article aims to consider the knowledge of the biological background of EGFR pathways in dissecting clinical studies of EGFR targeted treatment in breast ca...

journal_title：Expert opinion on investigational drugs

authors： Matsuda N,Lim B,Wang X,Ueno NT

更新日期：2017-04-01 00:00:00

abstract：BACKGROUND:Hematopoietic stem cell (HSC) transplantation is a treatment option for hematological malignancies. Current mobilization regimes frequently result in inadequate numbers of HSC for transplant therefore alternative methods of mobilization are required. OBJECTIVE:The chemokine receptor CXCR4 and ligand SDF-1 a...

journal_title：Expert opinion on investigational drugs

authors： Fricker SP

更新日期：2008-11-01 00:00:00

abstract：:Hepatitis C virus is the most common chronic, blood-bourne infection, affecting 170 million people worldwide, approximately 3% of the global population. Of those infected with hepatitis C virus, 50 - 85% will develop chronic hepatitis C. Although hepatitis C is primarily a disease of the liver, a diagnosis is currentl...

journal_title：Expert opinion on investigational drugs

authors： Pockros PJ

更新日期：2002-04-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:Antibacterial drug discovery and development has slowed considerably in recent years, with novel classes discovered decades ago and regulatory approvals tougher to get. Traditional approaches and the newer genomic mining approaches have not yielded novel classes of antibacterial compounds. Inste...

journal_title：Expert opinion on investigational drugs

authors： Devasahayam G,Scheld WM,Hoffman PS

更新日期：2010-02-01 00:00:00

abstract：BACKGROUND:Based partially on encouraging findings from preclinical models, interest has grown in therapeutic inhibition of NF-kappaB to limit inflammatory injury during sepsis. However, NF-kappaB also regulates protective responses, and predicting the net survival effects of such inhibition may be difficult. OBJECTIV...

journal_title：Expert opinion on investigational drugs

authors： Li X,Su J,Cui X,Li Y,Barochia A,Eichacker PQ

更新日期：2009-08-01 00:00:00

abstract：INTRODUCTION:About 185,000,000 people worldwide are chronically infected with hepatitis C virus (HCV). Currently, the most successful HCV infection antiviral therapies reduce the chance of progression towards the advanced phases of the hepatopathy (liver cirrhosis, hepatocellular carcinoma and death). Recently, however...

journal_title：Expert opinion on investigational drugs

authors： Gentile I,Zappulo E,Buonomo AR,Maraolo AE,Borgia G

更新日期：2015-01-01 00:00:00

abstract：:In addition to a variety of other novel agents, interest in histone deacetylase inhibitors (HDACIs) as antineoplastic drugs has recently accelerated and increasing numbers of these compounds have entered clinical trials in humans. HDACIs represent a prototype of molecularly targeted agents that perturb signal transduc...

journal_title：Expert opinion on investigational drugs

authors： Rosato RR,Grant S

更新日期：2004-01-01 00:00:00

abstract：:High-density lipoprotein (HDL) therapy is a novel and emerging area of therapeutic development in the cardiovascular field. It attempts to supplement and improve the vascular benefit exerted by other agents that are active on lipid metabolism, for example, hypolipidaemic drugs. Furthermore, it takes advantage of the n...

journal_title：Expert opinion on investigational drugs

authors： Marchesi M,Sirtori CR

更新日期：2006-03-01 00:00:00

abstract：INTRODUCTION:Basal-like breast cancer is characterized by being triple negative and aggressive. Defects in DNA repair is a promising therapeutic target as BRCA alterations are found in 11 to 42% of these tumors, with a frequency varying according to family history and ethnicity. The oral PARP inhibitors exploit this de...

journal_title：Expert opinion on investigational drugs

authors： Robert M,Frenel JS,Gourmelon C,Patsouris A,Augereau P,Campone M

更新日期：2017-06-01 00:00:00

abstract：INTRODUCTION:Studies in vitro and in vivo have identified several peptides that are potentially useful in treating systemic lupus erythematosus (SLE). The rationale for their use lies in the cost-effective production, high potency, target selectivity, low toxicity, and a peculiar mechanism of action that is mainly base...

journal_title：Expert opinion on investigational drugs

authors： Talotta R,Atzeni F,Laska MJ

更新日期：2020-08-01 00:00:00

abstract：:Phytoestrogens, such as the soya isoflavones genistein and daidzein, are currently being extensively investigated through both molecular, preclinical and clinical studies to determine their potential health benefits. Phytoestrogens may protect against chronic diseases such as hormone-dependent cancer (e.g., breast and...

journal_title：Expert opinion on investigational drugs

authors： Wiseman H

更新日期：2000-08-01 00:00:00

abstract：INTRODUCTION:Ewing sarcoma family tumors (ESFT) are a group of aggressive diseases, characterized histologically by small, round, blue cells and genetically by translocation involving EWS and ETS partner genes. The current treatment of localized Ewing sarcoma (ES) requires a multi-disciplinary approach, including multi...

journal_title：Expert opinion on investigational drugs

authors： Vornicova O,Bar-Sela G

更新日期：2016-06-01 00:00:00

abstract：:Argatroban, a synthetic peptidomimetic antithrombin agent, is the first clinical anticoagulant solely to target thrombin. For some time, this drug has been used in Japan for the management of thromboembolic disorders. Recently, it has been approved in Japan for use in thrombotic and ischaemic stroke. Despite a large n...

journal_title：Expert opinion on investigational drugs

authors： Jeske W,Walenga JM,Lewis BE,Fareed J

更新日期：1999-05-01 00:00:00

abstract：:Biologically-based skin substitutes have developed as commercial products over the last 5 years. The first generation includes the collagen-based synthetic device, Integra, and Alloderm, which is based on devitalised and cross-linked human dermis. These are used as dermal replacements for third degree burns. Within th...

journal_title：Expert opinion on investigational drugs

authors： Mansbridge J

更新日期：1998-05-01 00:00:00

abstract：INTRODUCTION:Heat shock protein 90 (HSP90) serves as a critical facilitator for oncogene addiction. There has been augmenting enthusiasm in pursuing HSP90 as an anticancer strategy. In fact, since the initial serendipitous discovery that geldanamycin (GM) inhibits HSP90, the field has rapidly moved from proof-of-concep...

journal_title：Expert opinion on investigational drugs

authors： Jhaveri K,Ochiana SO,Dunphy MP,Gerecitano JF,Corben AD,Peter RI,Janjigian YY,Gomes-DaGama EM,Koren J 3rd,Modi S,Chiosis G

更新日期：2014-05-01 00:00:00

abstract：:CGRP is a potent vasodilator that has been shown to have a physiological and/or pathological role in neurogenic inflammation, headaches including migraine, thermal injury, circulatory shock, pregnancy and menopause, hypertension and heart failure and is known to be cardioprotective. CGRP is also a positive inotrope an...

journal_title：Expert opinion on investigational drugs

authors： Doggrell SA

更新日期：2001-06-01 00:00:00

abstract：:INH-A21 is an experimental human immune globulin for intravenous infusion (IGIV) derived from donors specifically selected for elevated levels of antibodies against the Staphylococcal fibrinogen-binding proteins, serine aspartate dipeptide repeat G and clumping factor A. Phase II results demonstrated that infusions of...

journal_title：Expert opinion on investigational drugs

authors： Bloom BT

更新日期：2006-06-01 00:00:00

abstract：:Diabetes is a chronic, debilitating disease that afflicts millions of people worldwide and poor glycemic control in this disease leads to numerous microvascular and macrovascular complications. There is growing evidence that tight glycemic control prevents the development, and delays the progression, of microvascular ...

journal_title：Expert opinion on investigational drugs

authors： Mudaliar S

更新日期：2007-10-01 00:00:00

abstract：:Numerous studies over the last few years have suggested that modulating the glutamatergic system may be an efficient method to achieve an antidepressant effect. Data suggest that metabotropic glutamate receptors (mGlu receptors), related to long-term, modulatory effects on glutamatergic neurotransmission, may be a goo...

journal_title：Expert opinion on investigational drugs

authors： Palucha A

更新日期：2006-12-01 00:00:00